Mereo BioPharma Group plc Quarterly Operating Income (Loss) in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Mereo BioPharma Group plc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2023 to Q3 2024.
  • Mereo BioPharma Group plc Operating Income (Loss) for the quarter ending September 30, 2024 was -$9.37M, a 3.38% decline year-over-year.
  • Mereo BioPharma Group plc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$39.2M.
  • Mereo BioPharma Group plc annual Operating Income (Loss) for 2023 was -$28.4M, a 47.8% increase from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$39.2M -$9.37M -$306K -3.38% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$38.9M -$12.8M -$12M -1480% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$26.9M -$9.9M +$1.51M +13.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$28.4M -$7.13M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 -$9.07M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$811K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$11.4M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.